(NASDAQ: MRNA) Moderna's forecast annual revenue growth rate of 2.07% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.92%.
Moderna's revenue in 2025 is $3,078,000,000.On average, 7 Wall Street analysts forecast MRNA's revenue for 2025 to be $756,239,149,570, with the lowest MRNA revenue forecast at $675,286,826,249, and the highest MRNA revenue forecast at $853,329,723,052. On average, 11 Wall Street analysts forecast MRNA's revenue for 2026 to be $988,478,911,125, with the lowest MRNA revenue forecast at $708,988,914,801, and the highest MRNA revenue forecast at $2,204,720,443,041.
In 2027, MRNA is forecast to generate $1,285,208,642,402 in revenue, with the lowest revenue forecast at $866,912,497,369 and the highest revenue forecast at $3,086,375,172,403.